Crissy Dudgeon

1.4k total citations
19 papers, 981 citations indexed

About

Crissy Dudgeon is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Crissy Dudgeon has authored 19 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Crissy Dudgeon's work include Cancer-related Molecular Pathways (6 papers), Cell death mechanisms and regulation (3 papers) and Cancer Mechanisms and Therapy (2 papers). Crissy Dudgeon is often cited by papers focused on Cancer-related Molecular Pathways (6 papers), Cell death mechanisms and regulation (3 papers) and Cancer Mechanisms and Therapy (2 papers). Crissy Dudgeon collaborates with scholars based in United States, China and France. Crissy Dudgeon's co-authors include Jian Yu, Lin Zhang, Ettore Appella, Dmitry V. Bulavin, Sathyavageeswaran Shreeram, Oleg N. Demidov, Calvina Kek, Albert J. Fornace, Oleg Timofeev and Carl W. Anderson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Crissy Dudgeon

18 papers receiving 964 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Crissy Dudgeon United States 14 760 417 192 114 107 19 981
Mahesh Saqcena United States 18 661 0.9× 269 0.6× 199 1.0× 117 1.0× 100 0.9× 22 1.1k
Laura Zannini Italy 16 817 1.1× 335 0.8× 203 1.1× 138 1.2× 82 0.8× 24 1.0k
Cynthia Kosinski United States 9 695 0.9× 427 1.0× 156 0.8× 123 1.1× 218 2.0× 9 1.2k
Alper Yetil United States 5 951 1.3× 322 0.8× 208 1.1× 99 0.9× 59 0.6× 5 1.2k
Karuppiah Kannan United States 13 831 1.1× 427 1.0× 146 0.8× 113 1.0× 196 1.8× 29 1.1k
Gavin D. Grant United States 14 904 1.2× 326 0.8× 208 1.1× 179 1.6× 79 0.7× 17 1.2k
Xiaodong Liao China 12 902 1.2× 442 1.1× 303 1.6× 155 1.4× 174 1.6× 22 1.2k
Stuart Black United States 9 921 1.2× 637 1.5× 140 0.7× 117 1.0× 108 1.0× 9 1.2k
Daniel Y.L. Mao Canada 17 1.2k 1.5× 374 0.9× 154 0.8× 203 1.8× 74 0.7× 21 1.4k
Paola Infante Italy 26 1.3k 1.7× 392 0.9× 226 1.2× 69 0.6× 165 1.5× 46 1.5k

Countries citing papers authored by Crissy Dudgeon

Since Specialization
Citations

This map shows the geographic impact of Crissy Dudgeon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Crissy Dudgeon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Crissy Dudgeon more than expected).

Fields of papers citing papers by Crissy Dudgeon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Crissy Dudgeon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Crissy Dudgeon. The network helps show where Crissy Dudgeon may publish in the future.

Co-authorship network of co-authors of Crissy Dudgeon

This figure shows the co-authorship network connecting the top 25 collaborators of Crissy Dudgeon. A scholar is included among the top collaborators of Crissy Dudgeon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Crissy Dudgeon. Crissy Dudgeon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Tameire, Feven, Crissy Dudgeon, Kathryn Bieging-Rolett, et al.. (2025). In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation. Molecular Cancer Therapeutics. 25(1). 71–83.
2.
Dudek, Arkadiusz Z., Joyce O’Shaughnessy, Sarina A. Piha‐Paul, et al.. (2024). A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15118–e15118. 10 indexed citations
3.
Stokes, Michael E., Verónica Calvo, Sho Fujisawa, et al.. (2023). PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors. Clinical Cancer Research. 29(23). 4870–4882. 16 indexed citations
4.
Bieging-Rolett, Kathryn, Crissy Dudgeon, Michael E. Stokes, et al.. (2023). Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML. Blood. 142(Supplement 1). 2943–2943. 3 indexed citations
5.
Sethna, Zachary, Yuval Elhanati, Crissy Dudgeon, et al.. (2017). Insights into immune system development and function from mouse T-cell repertoires. Proceedings of the National Academy of Sciences. 114(9). 2253–2258. 26 indexed citations
6.
Dudgeon, Crissy, Yi Lan, Xin Yu, et al.. (2017). U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts. Molecular Cancer Therapeutics. 16(8). 1445–1455. 12 indexed citations
7.
Yu, Xin, Yi Lan, Crissy Dudgeon, et al.. (2016). 262. Therapeutic Suppression of the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts with U1 Adaptor Oligonucleotide / RGD Peptide Conjugates. Molecular Therapy. 24. S104–S104. 1 indexed citations
8.
Chiou, Shin‐Heng, Ian P. Winters, Jing Wang, et al.. (2015). Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes & Development. 29(14). 1576–1585. 165 indexed citations
9.
Levine, Arnold J., Chang S. Chan, Crissy Dudgeon, Anna M. Puzio‐Kuter, & Pierre Hainaut. (2015). The Evolution of Tumors in Mice and Humans with Germline p53 Mutations. Cold Spring Harbor Symposia on Quantitative Biology. 80. 139–145. 15 indexed citations
10.
Sun, Jing, Kan He, Dongshi Chen, et al.. (2014). Aurora Kinase Inhibition Induces PUMA via NF-κB to Kill Colon Cancer Cells. Molecular Cancer Therapeutics. 13(5). 1298–1308. 33 indexed citations
11.
Dudgeon, Crissy, Chang Chan, Yvonne Sun, et al.. (2014). The evolution of thymic lymphomas in p53 knockout mice. Genes & Development. 28(23). 2613–2620. 61 indexed citations
12.
Dudgeon, Crissy, Sathyavageeswaran Shreeram, Sharlyn J. Mazur, et al.. (2013). Genetic variants and mutations ofPPM1Dcontrol the response to DNA damage. Cell Cycle. 12(16). 2656–2664. 33 indexed citations
13.
Dudgeon, Crissy, et al.. (2012). Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene. 31(46). 4848–4858. 54 indexed citations
14.
Sun, Jing, Quanhong Sun, Matthew F. Brown, et al.. (2012). The Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMA. PLoS ONE. 7(8). e43158–e43158. 40 indexed citations
15.
Dudgeon, Crissy, Ellen X. Sun, Rui Peng, et al.. (2010). PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01. Molecular Cancer Therapeutics. 9(11). 2893–2902. 54 indexed citations
16.
Qiu, Wei, Crissy Dudgeon, Chuanshu Huang, et al.. (2009). PUMA is directly activated by NF-κB and contributes to TNF-α-induced apoptosis. Cell Death and Differentiation. 16(9). 1192–1202. 133 indexed citations
17.
Zhou, Guoli, et al.. (2009). Molecular cloning of the HGD gene and association of SNPs with meat quality traits in Chinese red cattle. Molecular Biology Reports. 37(1). 603–611. 18 indexed citations
18.
Shreeram, Sathyavageeswaran, Oleg N. Demidov, Hiroshi Yamaguchi, et al.. (2006). Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways. Molecular Cell. 23(5). 757–764. 289 indexed citations
19.
Dudgeon, Crissy, Calvina Kek, Oleg N. Demidov, et al.. (2006). Tumor Susceptibility and Apoptosis Defect in a Mouse Strain Expressing a Human p53 Transgene. Cancer Research. 66(6). 2928–2936. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mahesh Saqcena Breakdown of academic impact, for papers by Laura Zannini Breakdown of academic impact, for papers by Cynthia Kosinski Breakdown of academic impact, for papers by Alper Yetil Breakdown of academic impact, for papers by Karuppiah Kannan Breakdown of academic impact, for papers by Gavin D. Grant Breakdown of academic impact, for papers by Xiaodong Liao Breakdown of academic impact, for papers by Stuart Black Breakdown of academic impact, for papers by Daniel Y.L. Mao Breakdown of academic impact, for papers by Paola Infante
Rankless by CCL
2026